WO2012163088A3 - Médicament pour le traitement de maladies rénales et cardiaques et ses utilisations - Google Patents

Médicament pour le traitement de maladies rénales et cardiaques et ses utilisations Download PDF

Info

Publication number
WO2012163088A3
WO2012163088A3 PCT/CN2012/001010 CN2012001010W WO2012163088A3 WO 2012163088 A3 WO2012163088 A3 WO 2012163088A3 CN 2012001010 W CN2012001010 W CN 2012001010W WO 2012163088 A3 WO2012163088 A3 WO 2012163088A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart disease
medicine
treating kidney
kidney
medicines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2012/001010
Other languages
English (en)
Chinese (zh)
Other versions
WO2012163088A2 (fr
Inventor
梁广
潘勇
王怡
赵承光
李校堃
蔡露
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wenzhou Medical College
Original Assignee
Wenzhou Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenzhou Medical College filed Critical Wenzhou Medical College
Publication of WO2012163088A2 publication Critical patent/WO2012163088A2/fr
Publication of WO2012163088A3 publication Critical patent/WO2012163088A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la (2E,6E)-2,6-bis(2-(trifluorométhyl) benzylidène)cyclohexanone ou ses sels pharmaceutiquement acceptables destinés à être utilisés dans la préparation de médicaments pour traiter ou prévenir des maladies rénales ou cardiaques, ou à être utilisés dans des médicaments pour améliorer les symptômes de maladies rénales ou cardiaques.
PCT/CN2012/001010 2011-06-01 2012-07-27 Médicament pour le traitement de maladies rénales et cardiaques et ses utilisations Ceased WO2012163088A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110146331.2 2011-06-01
CN201110146331.2A CN102293763B (zh) 2011-06-01 2011-06-01 肾病和心脏病的治疗药物及其用途

Publications (2)

Publication Number Publication Date
WO2012163088A2 WO2012163088A2 (fr) 2012-12-06
WO2012163088A3 true WO2012163088A3 (fr) 2013-01-24

Family

ID=45354601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/001010 Ceased WO2012163088A2 (fr) 2011-06-01 2012-07-27 Médicament pour le traitement de maladies rénales et cardiaques et ses utilisations

Country Status (2)

Country Link
CN (1) CN102293763B (fr)
WO (1) WO2012163088A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293763B (zh) * 2011-06-01 2014-10-29 温州医学院 肾病和心脏病的治疗药物及其用途
CN110664790A (zh) * 2019-07-10 2020-01-10 温州医科大学 一种2,6-二(2-(三氟甲基)苯亚甲基)环己酮在药物制备中的应用
CN110615733B (zh) 2019-11-07 2021-09-03 温州医科大学 一种姜黄素衍生物的晶型i及其制备方法和应用
CN115998687B (zh) * 2022-11-04 2024-08-09 温州医科大学 一种姜黄素衍生物的固体分散体及其制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102038666A (zh) * 2009-10-18 2011-05-04 温州医学院 治疗或预防代谢疾病的药物及其应用
CN102293763A (zh) * 2011-06-01 2011-12-28 温州医学院 肾病和心脏病的治疗药物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102038666A (zh) * 2009-10-18 2011-05-04 温州医学院 治疗或预防代谢疾病的药物及其应用
CN102293763A (zh) * 2011-06-01 2011-12-28 温州医学院 肾病和心脏病的治疗药物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUANG LIANG ET AL.: "Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17, 2009, pages 2625 *

Also Published As

Publication number Publication date
CN102293763A (zh) 2011-12-28
CN102293763B (zh) 2014-10-29
WO2012163088A2 (fr) 2012-12-06

Similar Documents

Publication Publication Date Title
HK1198869A1 (en) Combination treatments for hepatitis c
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
MY192354A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
AR084309A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
BR112014012815A8 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12792006

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12792006

Country of ref document: EP

Kind code of ref document: A2